# A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

> **NCT03010527** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 217 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Bimekizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03010527
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-14
- **Primary completion:** 2018-09-25
- **Final completion:** 2018-09-25
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010527, "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03010527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*